Celleration Appoints Mark T. Wagner President and Chief Executive Officer Jul 1, 2009 01:31PM

EDEN PRAIRIE, Minn., July 1 /PRNewswire/ -- Celleration, Inc., developer of the patented MIST Therapy(R) System, an innovative device that uses ultrasound to heal wounds, has named Mark T. Wagner as president and chief executive officer and member of Celleration's board of directors. Mr. Wagner brings a successful track record of developing and commercializing medical devices spanning 30 years to the Celleration team. "We are delighted by the addition of Mark to the Celleration team," said Ed Spencer, Jr., Chairman of Affinity Capital Management and Chairman of Celleration's board of directors. "Mark brings a wealth of experience and a ...


Sofinnova Partners Leads Investment Round in CoAxia Jun 22, 2009 05:52PM

Funding of Stroke Company Exemplifies Firm's Strategy in the Field of Medical Device PARIS and MINNEAPOLIS, June 22 /PRNewswire/ -- Sofinnova Partners of Paris, France today announced having led a $21.5M financing in Minneapolis based medical device company CoAxia. The round also included participation from previous major investors Affinity Capital Management, Baird Venture Partners, Canaan Ventures Partners, Johnson and Johnson Development Corporation, and Prism Ventureworks. CoAxia is a company developing NeuroFlo(TM), a device providing perfusion augmentation developed for the treatment of ischemic stroke. The purpose of this Series D financing is to provide sufficient funds for CoAxia to complete its SENTIS pivotal trial, and to submit results to the US FDA. In addition, the funds will allow further investigation of NeuroFlo in combination with ...


CoAxia, Inc. Announces $21.5M Series D Financing Jun 22, 2009 05:51PM

Funding and Clinical Trial Progress Position Company for PMA Submission MINNEAPOLIS, June 22 /PRNewswire/ -- CoAxia, Inc. of Maple Grove, MN, announced today completion of a $21.5M Series D financing. The round was led by Sofinnova Partners with participation from all previous major investors including Affinity Capital Management, Baird Venture Partners, Canaan Ventures Partners, Johnson and Johnson Development Corporation, and Prism Ventureworks. In addition, CoAxia reported strong, continued enrollment in its SENTIS pivotal trial of NeuroFlo(TM) technology for acute ischemic stroke. The company has now enrolled over 75% of its goal of approximately 500 patients, with enrollment expected to conclude in early 2010, and PMA submission later that year. Also, the company announced that it has recently completed two pilot studies of its NeuroFlo catheter in additional stroke patient populations; a) those treated as late as 24 ...